Applications of Artificial Intelligence in Pharmaceutical Research: An Extensive Review

Introduction

In today’s world, AI has become an inseparable part of our present and future [1]. Due to the advances in computational power and the enormous amounts of digitalization, there is an ever-increasing wealth of data. AI uses the power of algorithms (computer programs) to make inferences by finding features from large amounts of data. Ultimately, the programming of the algorithm is in the hands of the scientists and clinicians who set up the underlying instructions that help the computer make decisions, such as classification. Hence, the algorithms are often based on information and understanding that we, humans, already have (supervised methods) so that predictions can be made using this knowledge. On the other hand, unsupervised methods from machine learning (ML) are where the algorithm manages to learn, analyze, and make inferences from data without human involvement. Thus, in case of a vast field such as precision oncology, there is great value in an open-ended approach such as ML, especially unsupervised algorithms. It would allow the practitioner to “see” information that may not have been evident to them directly. In addition, ML being independent in learning improves as more data become available. Artificial Intelligence (AI) is an interdisciplinary field that focuses on the development of intelligent machines capable of performing tasks that typically require human intelligence [2]. In recent years, AI has gained significant traction in the pharmaceutical industry due to its potential to optimize drug discovery and development processes and improve patient outcomes. Numerous industries are actively pursuing strategies to boost their progress in order to meet the ever-evolving demands and expectations of their customers. Among these sectors, the pharmaceutical industry holds a crucial position, playing a pivotal role in saving lives. With a strong focus on continuous innovation and the adoption of cutting-edge technologies, the pharmaceutical industry is at the forefront of addressing global healthcare challenges and responding to medical emergencies, such as the recent pandemic [3]. Innovation within the pharmaceutical sector is driven by extensive research and development efforts across diverse domains, including advanced manufacturing technologies, innovative packaging solutions, and customer- centric marketing strategies [4]. From the development of small drug molecules to biologics, there is a consistent emphasis on enhancing stability and potency to meet unmet medical needs. However, the evaluation of the potential toxicity associated with new drugs remains a significant concern, necessitating ongoing research and exploration. A primary objective is to deliver drug molecules that offer optimal benefits and suitability for use in the healthcare industry. Despite advancements, the pharmaceutical industry encounters various challenges that require further technological advancements to meet global medical and healthcare demands [5]. The demand for a skilled workforce in the healthcare sector is persistent, underscoring the importance of providing continuous training to healthcare personnel to enhance their effectiveness in routine tasks. Identifying skill gaps within the pharmaceutical industry is crucial, and addressing these gaps through appropriate remedial measures is essential. However, providing adequate training presents its own challenges. According to a report by certain authorities, approximately 41% of supply chain disruptions occurred in June 2022, making supply chain disruption the second most formidable challenge faced by the industry. Many pharmaceutical companies are anticipating further advancements in their supply chain and exploring innovative models to overcome these challenges, thereby enhancing business resilience [6]. The global outbreak of the coronavirus disease 2019 (COVID-19) has caused significant disruptions to various operations worldwide, including ongoing clinical trials [7]. These disruptions have underscored the importance of resilience and adaptability within the pharmaceutical industry as it continues to navigate through uncertain times. FDA plans to develop and adopt a flexible risk-based regulatory framework that promotes innovation and protects patient safety as AI/ML will undoubtedly play a critical role in drug development. The McKinsey Global Institute (MGI) has estimated that technology could generate $60 billion to $110 billion a year in economic value for the pharma and medical-product industries, because it can boost productivity by accelerating the process of identifying compounds for possible new drugs, speeding their development and approval, and improving the way they are marketed.

AI Applications in Drug Discovery

The use of artificial intelligence (AI) in medicinal chemistry has gained significant attention in recent years as a potential means of revolutionizing the pharmaceutical industry [9]. Drug discovery, the process of identifying and developing new medications, is a complex and time- consuming endeavor that traditionally relies on labor- intensive techniques, such as trial-and-error experimentation and high-throughput screening. However, AI techniques such as machine learning (ML) and natural language processing offer the potential to accelerate and improve this process by enabling more efficient and accurate analysis of large amounts of data [10]. The successful use of deep learning (DL) to predict the efficacy of drug compounds with high accuracy has been described recently by the authors LeCun Y, et al. [11]. AI-based methods have also been able to predict the toxicity of drug candidates [12]. These and other research efforts have highlighted the capacity of AI to improve the efficiency and effectiveness of drug discovery processes. However, the use of AI in developing new bioactive compounds is not without challenges and limitations. Ethical considerations must be taken into account, and further research is needed to fully understand the advantages and limitations of AI in this area [13]. Despite these challenges, AI is expected to significantly contribute to the development of new medications and therapies in the next few years. Per one report from McKinsey and company, titled “Generative AI in the pharmaceutical industry: Moving from hype to reality”, for In silico compound screening, Gen AI accelerates the screening process with foundational chemistry models that can map millions of known chemical compounds by their structure and function and overlay this information with known results for tested molecules. Like GPT-4, which is trained to predict the likely next word in a sentence, these models predict the next part (for example, an atom) in the structure of small or large molecule (such as an amino acid). Through much iteration, the model learns fundamental principles of large and small molecule chemistry. This knowledge can then be used to train bespoke machine learning models that offer more precise predictions in largely unexplored areas of chemistry that companies can prioritize for subsequent screening.

AI-Enabled Drug Repurposing

Machine learning plays an important role in studying drug repurposing, especially since the occurrence of COVID-19, scientists around the world used machine learning-based approaches to signal effective drugs. At present, there are still some problems, such as the black box problem of deep learning to signaling repurposable drugs causing hard to explain the rationality of the results. It is necessary to develop interpretable deep learning and causal learning along with the traditional drug discovery experiments. Furthermore, it is the fusion problem of the general field of machine learning in drug development, how to better characterize molecules and their conformational changes, to better extract the characteristics of molecules. By developing machine learning methods, we can accelerate drug discovery and improve human health in a way that has never been possible before. AI-driven approaches are facilitating drug repurposing efforts by identifying existing drugs that could be effective against new diseases or indications. This strategy accelerates the drug development timeline and reduces costs [14, 15].

AI in Predictive Analytics for Clinical Trials

Clinical trial analytics is crucial for advancing healthcare outcomes globally. The use of machine learning in clinical trial analytics holds promise for accelerating processes, enhancing patient stratification, and advancing precision medicine. Challenges remain, such as the need for high-quality, non-biased training data, which can unleash the potential of machine learning, while balancing privacy concerns. Addressing these challenges in a thoughtful and ethical manner will pave the way for more effective and inclusive clinical trial analytics, ultimately benefiting diverse patient populations and advancing the field of medical research. AI helps optimize clinical trial design by predicting patient recruitment rates, patient responses, and potential adverse events. This aids in improving trial efficiency and reducing costs [16, 17]. By using generative AI models built on data from medical imaging techniques such as X-rays, CAT scans, and MRIs, scientists could identify new biomarkers, deeply hidden visual signatures of disease activity and severity that lead to unforeseen new treatments. The cumulative result will be shorter, more efficient trials with a greater likelihood of success [18].

AI in Personalized Medicine and Precision Oncology

AI algorithms are enabling the analysis of patient- specific data to develop personalized treatment plans based on a patient’s unique genetic and molecular profile. The data-driven identification of disease states and treatment options is a crucial challenge for precision oncology. Artificial intelligence (AI) offers unique opportunities for enhancing such predictive capabilities in the lab and the clinic. AI, including its best-known branch of research, machine learning, has significant potential to enable precision oncology well beyond relatively well-known pattern recognition applications, such as the supervised classification of single-source omics or imaging datasets [19, 20].

AI In Drug Manufacturing & Regulatory Compliance

AI is being utilized in drug formulation to predict optimal drug delivery systems and improve manufacturing processes, leading to enhanced drug stability and bioavailability [21, 22]. AI algorithms analyze adverse drug reaction data from various sources, such as social media and electronic health records, to improve pharmacovigilance and drug safety surveillance [23, 24]. AI is applied to analyze healthcare data and market dynamics, helping pharmaceutical companies optimize drug pricing strategies and ensure better market access [25, 26]. AI can assist in the analysis of complex regulatory data, expediting the drug approval process and ensuring compliance with regulatory standards [27, 28]. During the drug development process, pharma companies needs to answer questions and requests from regulatory agencies and they often create bottlenecks that can delay the approval and market entry of new therapies. Gen AI enabled intelligence engines can help predicting potential questions/requests patterns for a given submission; rapidly crafting appropriate responses; and providing deeper intelligence to submission strategies. Gen AI’s predictive analytics can help teams proactively anticipate questions/requests, thus reducing their number, both initial and on follow-up. The insights generated will go on to inform regulatory strategy, risk management, and the broader R&D strategy [18].

Conclusion

Artificial intelligence (AI) has emerged as a transformative force in the pharmaceutical industry, reshaping traditional approaches to drug discovery, development, and patient care. This extensive review has highlighted the myriad applications of AI in various facets of the pharmaceutical sector, emphasizing its advantages, challenges, and future prospects. From expediting drug discovery processes to optimizing clinical trial design, AI-driven techniques such as machine learning and deep learning have revolutionized pharmaceutical research. By leveraging vast datasets and predictive analytics, AI accelerates target identification, enhances drug repurposing efforts, and enables personalized treatment approaches tailored to individual patients’ genetic and molecular profiles.

Moreover, AI plays a pivotal role in improving drug formulation and manufacturing processes, enhancing pharmacovigilance and drug safety surveillance, and supporting drug pricing and market access strategies. These advancements not only drive efficiency gains but also contribute to better healthcare outcomes and patient experiences. However, the integration of AI into existing workflows and regulatory compliance remains a challenge, necessitating collaborative efforts between AI developers, pharmaceutical companies, and regulatory authorities. Ethical considerations and data privacy concerns also require careful attention to ensure responsible AI deployment and safeguard patient interests. In conclusion, while AI holds immense promise for reshaping the pharmaceutical industry and advancing healthcare, addressing these challenges is crucial for realizing its full potential. With continued innovation, collaboration, and ethical oversight, AI stands poised to usher in a new era of precision medicine, driving impactful improvements in drug development and patient care on a global scale.